An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2014
At a glance
- Drugs Ramucirumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 20 Sep 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 20 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.